# TREC (NCT01165112)

> Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01165112
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: University of Washington
- Conditions: Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma
- Interventions: Bendamustine Hydrochloride; Carboplatin; Rituximab; Etoposide; Laboratory Biomarker Analysis
- Enrollment: 48
- Primary outcome: Maximally Tolerated Dose of Bendamustine Hydrochloride That Can be Combined With Rituximab, Carboplatin, and Etoposide Chemotherapy in Patients With Relapsed or Refractory Lymphoid Malignancies
- Primary outcome: Safety and Toxicity of This Regimen

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=trec-nct01165112